S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

$2.06
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$2.03
$2.59
50-Day Range
$1.67
$2.55
52-Week Range
$1.51
$3.38
Volume
1.90 million shs
Average Volume
690,054 shs
Market Capitalization
$311.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Erasca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
288.3% Upside
$8.00 Price Target
Short Interest
Bearish
10.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Erasca in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.95) to ($1.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

533rd out of 938 stocks

Pharmaceutical Preparations Industry

239th out of 417 stocks

ERAS stock logo

About Erasca Stock (NASDAQ:ERAS)

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

ERAS Stock Price History

ERAS Stock News Headlines

HC Wainwright Reiterates "Buy" Rating for Erasca (NASDAQ:ERAS)
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
ERAS Mar 2024 2.000 put
ERAS Mar 2024 2.500 call
Erasca Co-Founder Acquires 3.2% More Stock
See More Headlines
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ERAS
Fax
N/A
Employees
129
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+288.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-242,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.37 per share

Miscellaneous

Free Float
106,063,000
Market Cap
$311.25 million
Optionable
Optionable
Beta
1.13
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jonathan E. Lim M.D. (Age 52)
    Co-Founder, Chairman & CEO
    Comp: $940.32k
  • Dr. David M. Chacko M.D. (Age 40)
    CFO & Chief Business Officer
    Comp: $616.76k
  • Dr. Michael D. Varney Ph.D. (Age 66)
    Chairman of Research & Development, Scientific Advisory Board Member and Director
    Comp: $83.26k
  • Dr. Nik Chetwyn Ph.D.
    Chief Operating Officer
  • Mr. Ebun S. Garner J.D. (Age 52)
    Esq., General Counsel & Corporate Secretary
    Comp: $510.98k
  • Dr. Lisa Tesvich-Bonora Ph.D.
    Chief People Officer
  • Mr. Brian L. Baker CPA (Age 57)
    M.S., Senior Vice President of Finance
  • Ms. Chandra D. Lovejoy M.S. (Age 53)
    Chief Regulatory Affairs Officer
  • Dr. Robert Shoemaker Ph.D. (Age 43)
    Senior Vice President of Research
  • Dr. Shannon R. Morris M.D. (Age 54)
    Ph.D., Chief Medical Officer

ERAS Stock Analysis - Frequently Asked Questions

Should I buy or sell Erasca stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ERAS shares.
View ERAS analyst ratings
or view top-rated stocks.

What is Erasca's stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Erasca's shares. Their ERAS share price targets range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 288.3% from the stock's current price.
View analysts price targets for ERAS
or view top-rated stocks among Wall Street analysts.

How have ERAS shares performed in 2024?

Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS shares have decreased by 3.3% and is now trading at $2.06.
View the best growth stocks for 2024 here
.

Are investors shorting Erasca?

Erasca saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 9,020,000 shares, a drop of 8.9% from the February 29th total of 9,900,000 shares. Based on an average trading volume of 801,900 shares, the short-interest ratio is currently 11.2 days. Currently, 10.1% of the company's shares are short sold.
View Erasca's Short Interest
.

When is Erasca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ERAS earnings forecast
.

How were Erasca's earnings last quarter?

Erasca, Inc. (NASDAQ:ERAS) posted its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.05.

What ETF holds Erasca's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 40,125 shares of ERAS stock, representing 0.90% of its portfolio.

When did Erasca IPO?

Erasca (ERAS) raised $262 million in an initial public offering on Thursday, July 15th 2021. The company issued 17,500,000 shares at a price of $14.00-$16.00 per share.

Who are Erasca's major shareholders?

Erasca's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (5.36%), Vanguard Group Inc. (2.51%), Vanguard Group Inc. (2.51%), PFM Health Sciences LP (1.70%), Schroder Investment Management Group (1.27%) and Goldman Sachs Group Inc. (0.86%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start.
View institutional ownership trends
.

How do I buy shares of Erasca?

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ERAS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners